2016 News Releases
CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients
CSL released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.
Health Canada Approves CSL Behring’s AFSTYLA™ for the Treatment of Hemophilia A
Health Canada has approved AFSTYLA, CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.
CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting
Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.
The Lancet Respiratory Medicine Publishes RAPID Extension Study Data Confirming Disease-modifying Effect of Respreeza® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)
CSL Behring’s RAPID Extension Study data confirms disease-modifying effect of Respreeza® in patients with AATD.
CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial
AEGIS-1 Phase 2b study meets co-primary endpoints of hepatic and renal safety and demonstrates proof of mechanism - results were presented at AHA 2016.
AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP
Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.